A study testing whether a new weekly shot, tirzepatide, can help people with COPD lose weight.
- Who can join
- Adults 40 to 80, have COPD, BMI 27+.
- What you take
- tirzepatide, given as part of the study. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 3 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: COPD. Also studied in: Obesity & Overweight, Sarcopenia.
Full scientific study title: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD.
Who can join
Adults 40 to 80, have COPD, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 40-80 years
- Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁/FVC \< 0.70
- GOLD stage 1-3 COPD (FEV₁ \>30% predicted)
- Former smoker with a smoking history of at least 10 pack-years
- Body mass index (BMI) ≥27 kg/m² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg/m²
Key exclusion criteria
- Type 2 diabetes mellitus (HbA1c \> 6.5%)
- Pregnancy or breastfeeding
- Coagulopathy, defined as INR \> 1.4 or platelet count \<80,000/μL
- Active malignancy, including lung cancer
- Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone)
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
Ohio1 site
- Cleveland ClinicCleveland, Ohio
Timeline
Scheduled start: August 28, 2026. Expected completion: August 15, 2029. Last updated on ClinicalTrials.gov: August 5, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 10, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
